Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders, and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies, and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care fields.
Company Growth (employees)
Key People at Johnson & Johnson
Alex Gorsky
Dominic J. Caruso
Ronald A. Williams
Michael Sneed
Peter Fasolo
Paul Stoffels
Johnson & Johnson Office Locations
Johnson & Johnson Data and Metrics
Johnson & Johnson Financial Metrics
Revenue (FY, 2016) | 71.9 b |
Revenue growth (FY, 2015 - FY, 2016), % | 3% |
Gross profit (FY, 2016) | 50.2 b |
Gross profit margin (FY, 2016), % | 70% |
Net income (FY, 2016) | 16.5 b |
EBIT (FY, 2016) | 16.5 b |
Market capitalization (19-Sep-2017) | 370.7 b |
Cash (31-Dec-2016) | 19 b |
EV | 374.2 b |
- Source: SEC Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 71.3 b | 74.3 b | 70.1 b | 71.9 b |
Revenue growth, % | 4% | (6%) | 3% | |
Cost of goods sold | 22.3 b | 22.7 b | 21.5 b | 21.7 b |
Gross profit | 49 b | 51.6 b | 48.5 b | 50.2 b |
- Source: SEC Filings
| USD | Y, 2010 | Y, 2011 | Y, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|---|
Cash | 15.8 b | 19.4 b | 24.5 b | 20.9 b | 14.5 b | 13.7 b | 19 b |
Inventories | 7.9 b | 8.2 b | 8.1 b | 8.1 b | |||
Current Assets | 56.4 b | 59.3 b | 60.2 b | 65 b | |||
PP&E | 16.7 b | 16.1 b | 15.9 b | 15.9 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 13.8 b | 16.3 b | 15.4 b | 16.5 b |
Accounts Receivable | (632 m) | (247 m) | (433 m) | (1.1 b) |
Inventories | (622 m) | (1.1 b) | (449 m) | (249 m) |
Accounts Payable | 1.8 b | 955 m | 656 m |
| USD | Y, 2016 |
|---|---|
EV/EBIT | 22.6 x |
EV/CFO | 19.9 x |
Revenue/Employee | 566.7 k |
Debt/Equity | 0.3 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2 x |
Johnson & Johnson Operating Metrics
Show all operating metricsJohnson & Johnson Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Actelion Pharmaceuticals | January 26, 2017 | $30 b |
| Abott Medical Optics | September 16, 2016 | $4.3 b |
| Vogue International | June 02, 2016 | $3.3 b |
| Novira Therapeutics | November 08, 2015 | |
| XO1 | March 20, 2015 | |
| Alios BioPharma | September 30, 2014 | $1.8 b |
| Aragon Pharmaceuticals | June 17, 2013 | $1 b |
